North of Tyne, Gateshead and North Cumbria Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Tuesday 10th January 2023.**

Classification of products:

R = 'RED' drugs for hospital use only
A = 'AMBER' drugs suitable for use under Shared Care arrangements
G+ = 'GREEN PLUS Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role) but where the provision of additional information, or an information leaflet, may be appropriate to facilitate continuing treatment by GPs.
G = 'GREEN' Drugs where initiation by GPs is appropriate.

1) Requests deferred from previous meetings

Product	Approved	Refused	Deferred	Notes
None				

2) New Requests

Product	Approved	Refused	Deferred	Notes
Morphine Sulfate oral dispersible tablets (Actimorph®)			✓	Actimorph® has been requested as an alternative for patients who have difficulty manipulating small doses of morphine sulfate solution. Also supported by palliative care who see this as an alternative to Sevredol®. More expensive than morphine sulfate solution. This may have a role for the small number of patients who are ambulatory but need break through pain relief. Concerns were raised regarding the risk of diversion. Since that initial recommendation additional communications have been received. The committee agreed that these additional points should be considered by the APC pain management sub-group and that the FSC and APC chairs can take out of committee action based on their recommendations.
Fobumix Easyhaler® (Budesonide/ formoterol)	✓ G			Fobumix Easyhaler® has been requested to facilitate the implementation of a programme which aims to • reduce short acting beta agonist use by implementing a Maintenance and Reliever Therapy (MART) approach in asthma care, • to improve asthma outcomes and • to reduce the carbon footprint. ICS and SABA Easyhalers are already on formulary **Decision: Approved**

3) New formulations & extensions to use

Product	Approved	Refused	Deferred	Notes
None				

4) NHS England communications noted and endorsed by APC

• Specialised Services circulars: ○ SSC2431: NICE TA Consultation Document: nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma ○ SSC2432: TA518 Tocilizumab for Giant Cell Arteritis - Update to relevant prior approval form ○ SSC2433: Provider letter - NHS England Clinical Commissioning Policy - Rituximab in the management of Thrombotic Thrombocytopenic Purpura TTP ○ SSC2434: NHS England Clinical Commissioning Policy: Ziconotide (intrathecal delivery) for chronic cancer pain ○ SSC2436: Clinical Commissioning Policy 2009 Multi-grip Hands for Upper Limb Amputations or Congenital Limb Loss ○ SSC2437: NHS England Clinical Commissioning Policy: Canakinumab for patients with Still's disease refractory to anakinra and tocilizumab (adults & children >2 years) ○ SSC2440: Clinical Commissioning Policy: Rituximab for Idiopathic Membranous Nephropathy in Adults ○ SSC2441: NHS England Clinical Commissioning Policy: Fostemsavir for multi-drug resistant HIV-1 infection (Adults) ○ SSC2443: Clinical Commissioning Policy: Treatment of iron overload for transfused and non-transfused patients with chronic inherited anaemias (all ages) [URN2109] ○ SSC2444: clinical commissioning policy relating to the use of dabrafenib and trametinib for the treatment of BRAF-mutated anaplastic thyroid cancer (ATC). ○ SSC2445: NHS England Clinical Commissioning Policy: Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by Mycobacterium Avium Complex (MAC) that is refractory to current treatment options (adults and post pubescent children). ○ SSC2448: NICE TA 809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease ○ SSC2453: NICE TA FAD: pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer ○ SSC2454: NICE TA FAD: cabozantinib for previously treated advanced hepatocellular carcinoma ○ SSC2455: NICE TA Draft Guidance: trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments ○ SSC2457: NICE TA FAD: mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy ○ SSC2458: NICE TA FAD: nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma ○ SSC2459: National Orbis Drug Access Arrangements – darolutamide for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel ○ SSC2460: NHS England Clinical Commissioning Policy: Glucarpidase for the urgent treatment of methotrexate-induced renal dysfunction – Update	The formulary will reflect the SSC position

- Clinical commissioning policies
  - Baricitinib for patients hospitalised due to COVID-19 (Adults and Children aged 2 years and over)
  - Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19
  - Remdesivir for patients hospitalised due to COVID-19
  - Treatment of Hospital-Onset COVID-19 in Adults and Children
  - Treatments for Highest Risk Non-Hospitalised Patients (Adults and Children) with COVID-19

5) Northern (NHS) Treatment Advisory Group (N-TAG) recommendations

• NTAG CGM position statement • NTAG Decision Summary - sodium oxybate for narcolepsy - updated Nov 2022 • NTAG Decision Summary - vaginal devices for female urinary stress incontinence - updated Nov 2022 • NTAG Decision Summary - transanal irrigation systems - updated Nov 2022	The formulary will reflect the N–TAG position

6) Appeals against earlier decisions by the APC

Product	Approved	Refused	Deferred	Notes
None				

7) Guidelines. http://www.northoftyneapc.nhs.uk/guidance/

- Guidance/documents approved:
  - Update to gluten free guidance to correct a formatting error which changed units from 8 to 6 for women aged 19-74. Approved via chairs action.
  - COPD management
  - Dementia medicines
  - Abnormal LFTs
  - Tocilizumab
  - Vigabatrin
  - Bariatric guidelines
  - Erythropoietin
  - Third Party ordering
  - Ophthalmology- rebadged. Agreement reached that the lubricants section will be linked to the NoT formulary in the guideline to keep the document more current.
  - Testosterone - Reference ranges to be added by ML. Otherwise approved.
  - TRAMP2
  - Dronedarone RMOC SCG
  - Asthma in children: Full version and summary version
  - Angina
  - Constipation
  - Menopause – update
  - ENT referral guidelines
- Guidance to retire:
  - Removal of APC guidelines for prescribing in primary care: Non-valvular atrial fibrillation and replacement with Atrial Fibrillation - AHSN NENC (ahsn-nenc.org.uk)
  - Acne guidelines
- Guidance to extend:
  - Dexamphetamine in sleep disorders- extend by 12 months to allow for the RMOC process
  - ADHD - extend by 12 months to allow for the RMOC process
  - Methylphenidate for narcolepsy- extend by 12 months to allow for the RMOC process

8) Miscellaneous decisions by the APC

Pivmecillinam and Fosfomycin	Both products are currently Green plus on the formulary. To facilitate GP prescribing in line with NICE UTI guidance it was agreed that the RAG status should be changed to green.
Bempedoic acid	listed on formulary as a Green Plus treatment but in accordance with the NEELI guidance it should be Green.

Formulary Application Request Form	The form will be updated to add an additional question around whether the manufacturer has published a carbon reduction plan.
Opthalmology products review	ML and specialists at NUTH have reviewed the formulary choices for ocular lubricants. The new product list was accepted by the committee and the formulary will be updated accordingly.
Follitropin delta (Rekovelle®) injection	The addition of Rekovelle® to the formulary was approved in October 2019 for the purposes of a 100 patient evaluation only. The Formulary Subcommittee is satisfied the team are robustly monitoring their outcomes and therefore it was appropriate to leave Follitropin delta (Rekovelle®) on formulary
Nasal Naloxone (Nyxoid®)	This product will remain on formulary